Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-304 sodium salt tablets pharmacokinetics, safety, and pharmacodynamics study in obesity with prediabetes or type 2 diabetes
NL-OMON60115Phase 1Completed
- Sponsor
- Betagenon
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ATX304 in obesity, prediabetes and type 2 diabetes mellitus (T2DM), sponsored by Betagenon. Primary endpoint: Primary endpoint(s). Started Sep 2023; status: completed.
02
Drugs
ATX304
03
Conditions
obesityprediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON60115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60115.